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INTRODUCTION
            Breast cancer is the most common carcinoma in females which accounts  
for 22% of all female cancers. It is more than twice the occurrence of carcinoma in 
females at any other site.29 In southern India,  breast cancer is the second most 
common cancer among women.28 The incidence of the disease had been increasing 
in  both  developed  and  developing  countries  until  1980,  but  still  continues  to 
increase in the developing countries. 
            Breast disorders encompass a heterogenous group of lesions 
that may be presenting as a palpable mass, non-palpable abnormality 
detected on breast imaging or an incidental microscopic finding. 
Women who have undergone breast biopsies reflect a spectrum of 
histologic conditions from normal breast tissue of varying 
physiologic states at one extreme to changes approximating to 
carcinoma at the other end.60 
             Etiology of breast cancer is multifactorial. It includes diet, reproductive 
life style, exogenous and endogenous hormones, body weight, alcohol, smoking 
and physical activity. However, more than most other neoplasms, breast cancer 
shows familial clustering.29 Two high penetrance genes BRCA1 & BRCA2 greatly 
increase  the  cancer  risk.  Multigenic  traits  also  play  a  significant  role  in  the 
inherited susceptibility to cancer. Literatures say carcinoma breast is a disease of 
affluent  societies  which  have acquired the  western  style  characterized by  high 
calorie diet combined with lack of exercise.29
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             There  have  been  two general  approaches  to  prognostication  via 
histopathologic  analysis.  The  first  categorizes  carcinomas  based  on  specific 
features,  recognizing  the  so  called  special  type  carcinoma.  Histopathologic 
features have been recognized as a necessary element for appropriate management 
of breast carcinoma. The second approach evaluates individual characteristics of 
the carcinoma – grading which is shown to be robust determinant of outcome of 
breast carcinoma.15 Establishment of a uniform system of grading will increase the 
frequency of grading by pathologists, significantly reduce observer variation and 
strengthen the predictive value of histologic grade. 
          The most widely accepted system for grading invasive breast carcinoma is  
the  Elston-Ellis  system which  represents  the  modification of  the  Scarf-Bloom-
Richardson system established in the middle of the last century. It is performed by 
combining  tissue  architecture  (tubule  formation),  cell  morphology  (nuclear 
pleomorphism) and assessment of cell proliferation rate (Mitotic count).24,29,35,36,52.
          Histological grading has been considered as too subjective to be used 
clinically and grading may be associated with lack of reproducibility even when 
performed by experienced pathologists. On the other hand, numerous studies have 
shown a significant association between histological grade and survival in breast 
cancer  and there  is  no  doubt  that  grading is  simple,  quick  and economical  to 
perform. Low histological grade is significantly related to recent or current use of 
combined hormone replacement therapy.42  Histological grading identifies patients 
with low risk of breast cancer recurrence. Since it is associated with minimal cost,  
its use in clinical decision making may result in substantial savings. Omission of 
grading from clinical decision making results in overseas of adjuvant therapies.
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          Histological grade was correlated strongly with survival. Women with well  
differentiated node negative cancer had 97% 5year distant disease free survival 
rate as compared with 78% for women with poorly differentiated cancer.39  The 
relative importance of histologic grade in multivariate analysis  may depend on 
many factors such as the selection process of breast cancers for the series being 
analyzed, the quality of assessment, end points chosen and personal skill of the 
pathologist responsible for grading.39 
           It is important to evaluate the prognostic value of histologic grade in 
relation to novel molecular genetic markers. It remains to be seen whether some of 
the novel biologic factors can replace histologic grade as a simple and powerful 
prognostic variable and produce superior result when performed in routine clinical 
setting. A recent study indicates that grade may yet be a more powerful predictor 
than intensively studied molecular genetic factors such as P53 and Cerb-2.39
           This study is undertaken in view of evaluating the actual incidence of breast  
neoplasms  in  semi-urban  areas  like  Thanjavur  with  particular  attention  to 
demographic characteristics, clinical presentation, histopathology and grading.
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AIM OF STUDY
1. To evaluate the incidence and prevalence as well as trend of Breast
       neoplasms in semi-urban area.
 
2. To evaluate the clinical features, symptoms and signs associated with 
Breast malignancies.
 
3. To evaluate the malignant tumours of breast by histological grading.
 
4. To evaluate the initial role of histochemical stains in diagnosis of Breast 
      neoplasms.
 
5. To study the role of immunohistochemistry in doubtful cases. 
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MATERIALS AND METHODS
             The study group comprises of 267 breast neoplasm received from January 
2005  to  December2006  at  Thanjavur  Medical  College,  treated  by  either 
lumpectomy or mastectomy (simple/modified radical). The detailed history with 
particular attention to family history, socio-economic status,  radiation, nutrition 
and  parenteral  occupation  were  elicited  for  each  case.  A  thorough  clinical 
evaluation, routine haematological investigations, ultrasonogram and CT scan (in 
proportion of cases with possibility of distant metastasis) was done in every case. 
          In proportion of cases, initial evaluation with fine needle aspiration (FNA) 
was also done. FNA smears were fixed in isopropyl alcohol and processed with 
both routine H & E and Giemsa stains (Appendix I, II). 
            The received specimens, both lumpectomy as well as mastectomy were 
bisected  initially  and  fixed  properly  with  neural  buffered  formalin.  Small 
lumpectomy specimens of size less than 1cm were submitted to toto. In larger 
specimens, multiple sections were taken at 1cm interval. Mastectomy specimens 
were opened at 1cm interval like opening a book with special attention to include 
base,  both  lateral  margins,  skin  and  ulcerated  areas.  The  tissue  sections  were 
processed routinely, 3-5u sections were cut and stained with H & E. 
          In all cases cytomorphological evaluation was done to grade the neoplasm. 
In mucinous/colloid carcinoma of the breast, histochemical stains were also done 
to  identify  mucin  (Appendix  III).  In  doubtful  cases,  immunohistochemical 
evaluation with markers such as smooth muscle actin and myoglobin was also 
done. 
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REVIEW OF LITERATURE
         Breasts are often described as modified sweat glands resting on pectoral  
muscle.The breast  epithelium is  arranged in the form of  10-15 segments,  each 
consisting of a branching structure that has been likened to a flowering tree. The 
lobules drain into ductules and ducts which in turn drain into the collecting ducts 
onto the surface of the nipple. Just below the nipple the ducts are expanded by 
lactiferous sinuses.
. 
         The breast epithelium is arranged in the form of a lobule. The lobule together 
with its terminal duct has been called the terminal duct lobular unit (TDLU).Most 
pathologic lesions arise from this area. The normal lobule consists of a variable 
number of blind ended terminal ductules alternatively called acini which has a 
typical double epithelial  cell  layer.  The inner epithelium with its secretory and 
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absorptive  functions  is  cuboidal  or  columnar.  The  outer  layer  is  the  basal  or 
myoepithelial layer. The acini are surrounded by loose fibro vascular intralobular 
stroma which contrasts with the dense interlobular stroma.The nipple has large 
collecting (lactiferous) duct associated with sebaceous apparatus opening onto the 
surface. 
    At puberty, the female breast develops its characteristic adult structure. Minor 
variations occur during the menstrual cycle, but major physiological changes are 
seen  during  pregnancy  and  lactation.  During  menopause  there  is  a  major 
regression of breast tissue which merges with the atrophy associated with aging. 
Physiological  changes  result  in  radically  different  histological  appearances  at 
varying  ages.  These  changes  should  be  differentiated  and  compared  with  the 
pathological processes which occur in breast. 
BENIGN NEOPLASMS
FIBROADENOMA 
        Fibrodenoma  occurs  most  frequently  in  women  of  child  bearing  age, 
especially  under  30.Grossly,  fibrodenoma  is  a  sharply  demarcated  firm  mass 
grayish in colour with a slightly lobulated pattern and slit-like spaces.
Histopathology  comprises  of  admixture  of  stromal  and  epithelial 
proliferations  in  two  distinct  patterns  –  pericanalicular  pattern  as  a  result  of 
proliferation  of  stromal  cells  around  ducts  in  a  circumferential  fashion  and 
intracanalicular pattern due to compression of ducts into clefts by the proliferating 
stromal cells. 
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The stromal component may sometimes exhibit hypercellularity,  atypical 
bizarre multinucleated giant cells, extensive myxoid changes or hyalinization with 
dystrophic calcification and rarely ossification.29
          Fibrodenomas that contain cysts larger than 3mm, sclerosing adenosis,  
epithelial  calcifications or papillary apocrine change have been called complex 
fibroadenomas. Complex fibroadenomas were associated with a greater risk for 
subsequent breast cancer than fibroadenomas lacking such changes.52 
         Malignant changes in fibroadenomas were found only in 0.1% of cases35. 
The  risk  of  invasive  cancer  was  2.17  times  higher  among  patients  with 
fibrodenoma and  relative  risk  increased  to  3.10  among patients  with  complex 
fibrodenoma.61 They  usually  involve  the  epithelial  component  Sarcomatous 
transformation  of  the  stroma  of  fibrodenoma  is  an  even  rarer  phenomenon. 
Possibly only one case had a focal appearance of an osteosarcoma 35
           Juvenile fibroadenomas are characterized by increased stromal cellularity 
and epithelial hyperplasia. It should be distinguished from phyllodes by absence of 
leaf like projections and periductal stromal cellularity. Distinction between the two 
is important since Juvenile fibroadenoma is treated by excision with preservation 
of surrounding breast tissue whereas in phyllodes, a rim of normal tissue should be 
included in the excision.52 
TUBULAR ADENOMA
           They occur mainly in young adults. They are firm, well circumscribed and 
homogenous  with  a  uniform  yellowish  cut  surface.  Histological  examination 
shows proliferating tubules closely packed together with little or no surrounding 
fibrous stroma. The tubules are lined by a double cell layer. The tubular lumen is 
small,  often  empty  but  eosinophilic  proteinaceous  material  can  be  present. 
Combined tubular adenoma and fibroadenoma has been described.29,35,52.
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LACTATING ADENOMA 
          This presents as a solitary or multiple freely movable breast mass during 
pregnancy or puerperium. It may develop in ectopic locations such as axilla, chest 
wall or vulva.35,52  Grossly the lesion is well circumscribed with grey or tan cut 
surface. Microscopically, proliferated glands are seen lined by actively secreting 
cuboidal cells.Hyperplastic lobules show marked cytoplasmic vacuolization.35,52
INTRA-DUCTAL PAPILLOMA 
           It can arise in large or small ducts in the subareolar region with bloody  
nipple discharge. Microscopically, papillomas are intricately arborescent with the 
presence of two cell types, normochromatic and often oval nuclei, scanty mitotic 
activity and absence of necrosis. Multiple grossly detectable papillomas have been 
found to be either associated with or develop into carcinoma at a frequency higher 
than that expected from chance alone.35,52.The relative risk of invasive carcinoma 
for women with papillomas containing atypical hyperplasia was more than four 
times than that of without atypical hyperplasia.22,49.
PHYLLODES TUMOUR 
             Phyllodes tumour forms firm lobulated masses of varying sizes between 2 
and 40cm diameter mostly seen in middle aged women. They are usually well 
circumscribed   with a characteristic whorled pattern with visible clefts.
Phyllodes tumours exhibit an enhanced intracanalicular growth pattern with leaf 
like projections into dilated lumens. The epithelial component consists of luminal 
epithelial and myoepithelial cells. There is increased periductal stromal cellularity. 
Hyalinization or myxoid changes may be seen. 
             Malignant phyllodes have infiltrative rather than pushing margins. Stroma 
usually  shows  fibrosarcomatous  changes.  Heterologous  differentiation  such  as 
liposarcoma, osteosarcoma, chondrosarcoma or rhabdomyosarcoma may occur.
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Due  to  overgrowth  of  sarcomatous  components,  epithelial  component  can  be 
identified  only  after  multiple  sections.29 Norris  and  Taylor  used  3  characters 
together as determinants of malignant potential. Those are stromal cellular atypia, 
mitotic activity and nature of tumour margin (pushing Vs infiltrating).
              Pretraszka and Barnes refined the criteria of mitosis with classification as
Benign: (0 – 4 mitosis / 10hpf)
Borderline: (3 – 9 mitosis / 10 hpf, pushing or infiltrating margins, stromal  
cellular atypia).   
Malignant : (10 or more mitosis / 10 hpf), infiltrating margins, moderate to marked 
stromal cellular atypia.26
MYOEPITHELIAL LESIONS 
               These are lesions either derived from or composed of dominant to pure  
population of myoepithelial cells.    
CLASSIFICATION OF MYOEPITHELIAL LESIONS 
1) Myoepitheliosis 
a. Intraductal 
b. Periductal
2) Adenomyoepithelial adenosis 
3) Adenomyoepithelioma
a. Benign
b. With malignant change 
                            Myoepithelial carcinoma arising in an adenomyoepitheloma
Epithelial carcinoma arising in an adenomyoepitheloma
Malignant epithelial and myoepithelial components. 
Sarcoma arising in adenomyoepitheloma. 
Carcinosarcoma arising in an adenomyoepitheloma. 
4) Malignant myoepithelioma (myoepithelial carcinoma)
ADENOMYOEPITHELIOMA 
            This is composed of a predominantly and usually solid proliferation of  
phenotypically variable myoepithelial cells around small epithelial lined spaces. 
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            The tumour may display a spindle cell, tubular or most often a lobulated 
growth pattern. Myoepithelial cells range from clear to eosinophilic and hyaline     
(plasmacytoid) types.29     Microscopically there is a   balanced proliferation of 
round, oval or lobular glandular elements with intervening islands and bands of 
polygonal myoepithelial cells with clear cytoplasm. In some tumours,  the clear 
myoepithelial cells are numerous resulting in extensive zones virtually devoid of 
glands.  Epithelial  cells  tend  to  have  sparse,  darkly  staining  cytoplasm  and 
hyperchromatic nuclei.    
            Squamous, apocrine and sebaceous metaplasia may be present focally.In 
very  rare  instances  epithelial  component  exhibits  exaggerated  proliferations 
accompanied  by  cytologic  atypia  and  mitosis  that  may  constitute  carcinoma 
arising in adenomyoepithelioma. Sarcomas and carcinosarcomas also can occur in 
this  setting.  Rarely  both  components  may  develop  into  either  separate 
malignancies or a single malignant  infiltrative  tumour.29
NIPPLE ADENOMA 
       This is also known as florid papillomatosis of the nipple ducts. It usually 
occurs  in  the  fourth  of  fifth  decade  and  is  accompanied  by  serous  or  bloody 
discharge.29,35,52.Microscopically  it  is  composed  of  haphazardly  arranged 
proliferating tubular structures surrounded by varying amounts of fibrous stroma. 
It shows an abrupt junction with stratified squamous epithelium. The tubules are 
bilayered. The epithelial cells are usually cuboidal or columnar but apocrine and 
squamous metaplasia  can occur.           
MYOFIBROBLASTOMA 
         This  spindle  cell  tumour  is  a  very  rare  tumour  consisting   of  well 
circumscribed nodular  mass   of  haphazardly  arranged bundles  of  spindle  cells 
interspersed with bundles of collagen.29,35,52 
FAT NECROSIS 
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          Fat necrosis assumes importance because it can simulate carcinoma both  
clinically  and  mammographically.47  Fat  necrosis  more  commonly  results  from 
prior  surgical  intervention  or  radiation  therapy  while  a  history  of  antecedent 
trauma  may  also  be  obtained.  The  lesion  excised  early  in  the  course  of  its 
evolution contains histiocytes with foamy cytoplasm, as well as larger lipid filled 
cysts  and  occasional  multinucleated  giant  cells.  An  infiltrate  of  chronic 
inflammatory  cells  including  lymphocytes,  plasma  cells  and  cosinophils  are 
present. As the process evolves, the lesion becomes surrounded by dense fibrosis 
with progressive encapsulation and foci of calcification. 
 CARCINOMA BREAST
            
          Breast carcinoma is the most common malignant tumour and the leading 
cause of carcinoma death in women with more than 1,000,000 cases occurring 
world wide annually.35,52. Several risk factors for the development of breast cancer 
have been established such as family history, exogenous or endogenous estrogen 
and  nulliparity.  The  common  denominator  for  these  factors  is  strong  and 
prolonged  oestrogen  stimulation  operating  on  a  genetically  susceptible 
background.24,29,35,36,52. The  genes  responsible  for  hereditary  predisposition  have 
been identified on chromosomes 17q and 13q and named as BRCA1; BRCA2 
respectively29,35.
INSITU CARCINOMA 
          The term insitu carcinoma is used to describe a proliferation of presumably 
malignant epithelial cells that remain at their site of origin confined by a basement 
membrane.Insitu carcinoma is divided into ductal and lobular types based on the 
architectural  and cytologic features of proliferation rather  than on its  anatomic 
location within the ductal-lobular system because it is thought that both types arise 
from the terminal ductal lobular units35, 52.
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DUCTAL CARCINOMA IN SITU 
           It is a neoplastic intraductal lesion characterized by increased epithelial  
proliferation with subtle to marked cellular atypia. The incidence rate is 3 – 5% of 
breast  cancers  4,40.  Traditionally  DCIS  has  been  classified  on  the  basis  of 
architectural  pattern but now the recent International consensus conference has 
recommended that grading of DCIS should form the basis of classification 35,52. 
 Low grade DCIS is  composed of small  monomorphic cells  growing in 
arcades, micropapillae, cribriform or solid patterns. The nuclei are of uniform size 
with  regular  chromatin  pattern  and inconspicuous  nucleoli.  Mitotic  figures  are 
rare. Microcalcification are of the psammomatous type29,52. 
Intermediate grade DCIS form solid, cribriform or micropapillary patterns 
with some containing intraluminal necrosis.  Nuclei exhibits  occasional nucleoli 
and coarse chromatin29. The recurrence rate is 10% 44.
           High grade DCIS is composed of markedly pleomorphic, poorly polarized 
cells with irregular contour and distribution forming micropapillae, cribriform and 
solid patterns with characteristic comedo necrosis29. This is associated with local 
recurrence  of  19%  44. Unusual  variants  of  DCIS  are  composed  of  spindled, 
apocrine, signet ring, neuroendocrine, squamous or clear cells       
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VAN NUYS PROGNOSTIC INDEX SCORING OF DCIS 24,52.
Gross and Microscopic finding         Score 
Lesion size ≤  1.5cm 1
1.6 – 4cm 2
≥  4.1cm 3
Margins ≥  1.0cm 1
0.1 – 0.9cm 2
< 0.1cm 3
Grade Non High grade nuclei, no necrosis 1
Non High grade nuclei with necrosis 2
High grade nuclei with or without necrosis 3   
           Lesions with score of 3 or 4 receive only surgical treatment. A score of 5 –7 
receive local  surgical  and radiation treatment.  Scores  of  8  and 9 receive local 
surgical and radiation treatment with the caveat that recurrence rate may be as high 
as 40%. Careful follow up for patients at  increased risk for local recurrence is 
warranted 12. 
PAPILLARY DUCTAL CARCINOMA  IN SITU
           This lesion is located within a variably distended duct and characterized by  
multiple papillary processes with thin fibrovascular stalks and are totally devoid of 
a  myo-epithelial  cell  layer.  The  malignant  epithelial  cells  usually  have  a 
monomorphic appearance with tall oval nuclei lying perpendicular to the core35,50. 
Concomitant DCIS may be present in the surrounding breast tissue.
Solid and transitional type of variants have been described 29.
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LOBULAR CARCINOMA IN SITU 
            In LCIS, lobular architecture is retained and individual acini are enlarged 
and  distended  in  contrast  to  surrounding  lobules.  The  lumina  are  completely 
obliterated . The monomorphic cells filling the  lumina are smaller than those in 
DCIS  but  larger  than  normal  epithelial  cells  with  less  pronounced  nuclear 
pleomorphism and they exhibit notable feature of lack of cellular cohesion.34,52The 
reported incidence of subsequent breast cancer ranges from 17% to 37%. 
Invasive carcinoma that develops in these patients is mostly of ductal origin than 
of lobular origin 41.
INVASIVE  CARCINOMA
              Infiltrating breast cancers constitute a heterogenous group of lesions that  
differ in clinical presentation, radiographic characteristics, pathologic features and 
biologic potential.
The most common histologic type of invasive breast  cancer  by far is  invasive 
(infiltrating) ductal carcinoma “not classified into any of the other categories of 
invasive mammary carcinoma”. The specific histologic types are invasive lobular, 
tubular, mucinous, medullary and other rare types. In general special type cancers 
comprise  approximately  20% to  30% of  invasive  carcinomas  and  atleast  90% 
should demonstrate the defining histology characteristics of  a special type cancer 
before it is designated as being of that histologic type.  
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INFILTRATING DUCTAL CARCINOMA – NOS
It is a type of carcinoma that is without any special feature that would allow 
it to be classified as one of distinctive subtypes.
          Gross appearance has an irregular stellate outline.
          Microscopically architectural arrangement may be in cords, clusters and 
trabeculae  while  some  are  characterized  by  predominantly  solid  or  syncytial 
infiltrative pattern. Glandular differentiation may be present as tubular structures 
with  central  lumina.  Carcinoma  cells  have  variable  appearance  of  uniform  to 
pleomorphic  nuclei  with  abundant  eosinophilic  cytoplasm.  Degree  of  mitotic 
activity  varies.  Necrosis  may  be  focal  or  extensive.  Foci  of  elastosis  may  be 
present in periductal or perivenular regions.
            Mixed type carcinoma comprises of ductal NOS pattern in 10% - 40% of 
tumour and the rest being of a recognized special type 29. Pleomorphic carcinoma is 
a rare variant of  high grade ductal NOS characterized by pleomorphic and bizarre 
giant cells in more than 50%of tumour  cells in a background of adenocarcinoma 
or  adenocarcinoma with spindle  and squamous differentiation .Carcinoma with 
osteoclastic type of giant cells and choriocarcinomatous features have also been 
reported 29.
INFILTRATING LOBULAR CARCINOMA
            These tumours frequently present as irregular and poorly delimited 
tumours.The  malignant  cells  are  composed  of  single  lines  of  cells  and  lack 
cohesion (Indian file pattern).  In the targetoid or bull’s eye pattern, the tumour 
cells  are arranged in concentric rings around ducts and lobules. “ Skip areas” i.e 
foci of infiltrating carcinoma separated by areas of uninvolved mammary tissue 
are  a  common  feature  of  lobular  carcinoma.Solid,  tubulolobular,  alveolar  and 
pleomorphic variants are some of the special variants that have been described 52. 
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TUBULAR CARCINOMA 
            Tubular  carcinoma is  usually  smaller  than 2cm and there are  two  
morphologic types, ‘pure type’ with stellate nature and ‘sclerosing type’ with more 
diffuse ill defined structure 29. 
             Microscopically, it consists of irregularly arranged tubules lined by a 
single layer of epithelial cells with little pleomorphism and low mitotic rate. The 
tubules are characteristically angulated and have open glandular lumina 35,52.
MUCINOUS CARCINOMA 
              Mammary mucinous carcinomas are also known as colloid, mucoid or 
gelatinous  carcinomas.  They  have  rounded  outline  and  soft  texture  with 
characteristic glistening gelatinous appearance. Histologically the tumour consists 
of  small  islands  or  clusters  of  epithelial  cells  floating in  lakes  of  extracellular 
mucin  divided  by  delicate  fibrous  septae.  Intraepithelial  component  is 
characterised by micropapillary to solid pattern. The lakes of mucin are positive 
for  mucicarmine and periodic  acid Schiff  (PAS)  stains.  Traditionally  pure  and 
mixed variants of mucinous carcinoma have been described.  Pure type is further 
divided into cellular variant with intracytoplasmic mucin and hypocellular variant. 
 MEDULLARY CARCINOMA 
          Medullary carcinoma  are soft, fleshy and circumscribed.On microscopic 
examination,  syncytial  growth  pattern,  circumscription  and  lymphoplasmocytic 
response  are  most  important  of  the  diagnostic  criteria  .Nuclear  pleomorphism, 
prominent nucleoli and frequent mitotic figures are present. Tumour giant cells are 
not uncommon.  Those tumours that do not conform precisely to these criteria has 
been classified as ‘atypical medullary carcinoma’52.
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INVASIVE PAPILLARY CARCINOMA.
          Invasive  papillary  carcinomas  are  diagnosed  predominantly  in 
postmenopausal  patients.  Microscopically  they  are  characteristically 
circumscribed, show delicate or blunt papillae with focal solid areas of tumour 
growth. They may exhibit apical snouting of cytoplasm. The nuclei of tumour cells 
are typically intermediate grade. DCIS is present in more than 75% of cases and 
usually  but  exclusively  has  papillary  pattern.  Calcification are  commonly  seen 
histologically but usually are present in associated DCIS 29. They have an excellent 
prognosis 35,37.
INVASIVE MICROPAPILLARY CARCINOMA 
            Micropapillary carcinoma consists of hollow aggregates of malignant cells  
which  on  cross  section  have  the  appearance  of  tubules  with  diminished  or 
obliterated  lumens.  Tumour  cell  clusters  lie  within  artefactual  stromal  spaces 
caused  by  shrinkage  of  the  surrounding  tissue.   .  Nuclear  pleomorphism  is 
moderate,  mitotic activity is  low and there is  neither necrosis  nor lymphocytic 
reaction 29.
METAPLASTIC CARCINOMAS 
            Carcinomas showing extensive metaplastic  change to spindle cells,  
squamous cells and heterologous mesenchymal elements have been applied the 
term metaplastic carcinoma. 
CLASSIFICATION (WHO)*29 
• Purely epithelial 
• Squamous         
 Large cell keratinizing 
 Spindle cell 
 Acantholytic 
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• Adenocarcinoma with spindle cell differentiation. 
• Adenosquamous including muco-epidermoid. 
• Mixed epithelial and mesenchymal 
 Carcinoma with chondroid metaplasia. 
 Carcinoma with osseous metaplasia. 
 Carcinosarcoma. 
             The metaplastic spindle cell and squamous cell carcinomas may present in 
a  pure  form  without  any  admixture  with  a  recognizable  adenocarcinoma. 
Extensive  sampling  of  metaplastic  tumours  should  be  done  to  identify 
carcinomatous  foci  and  distinguish  them  from  true  sarcomas  because  of 
differences  in  biologic  behaviour  and  response  to  therapy.  Matrix  producing 
carcinomas are those which show an apparently abrupt transition from carcinoma 
to an osseous or cartilaginous matrix without an intervening transitional phase35,52. 
             Spindle cell carcinoma is composed of predominantly   bipolar spindle 
cells of relatively bland appearance with only mild or moderate atypia arranged in 
interweaving bundles.  Such tumours frequently also contain areas of squamous 
differentiation.  Matrix  producing  carcinomas  and spindle  cell  carcinomas  have 
generally favourable prognosis52.When the mesenchymal component is malignant 
the designation of carcinosarcoma is used, which has an aggressive behaviour59.
Among  squamous  cell  carcinomas,  acantholytic  variant  is  a  very  aggressive 
tumour29. 
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OTHER RARE TYPES 
          Various entities such as infiltrating cribriform type, lipid rich carcinoma, 
secretory carcinoma, oncocytic carcinoma, adenoid cystic carcinoma, acinic cell 
carcinoma,  glycogen  rich  clear  cell  carcinoma,  apocrine  carcinoma,  sebaceous 
carcinoma,inflammatorycarcinoma,neuroendocrinetumours,Adenomyoepithelioma 
and  malignant  myoepithelioma  have  been  reported  in  the  literature29 
Hematological malignancies can also affect the breast. Diffuse large cell NHL  is 
the most common14. 
OTHER MALIGNANT STROMAL TUMOURS 
            Stromal sarcoma is the generic term given to malignant breast tumours  
thought to arise from the specialized stroma of this organ but lacking an epithelial 
component  with  a  phyllodes  pattern.Microscopically,  most  of  them  have  the 
features  of  fibrosarcoma, focal  osseous metaplasia  can occur.  Stromal  tumours 
with an appearance equivalent to various  types of sarcomas include liposarcoma7, 
leiomyosarcoma6,  rhabdomyosarcoma,  fibrosarcoma,34 malignant  fibrous 
histiocytoma,  chondrosarcoma,8osteosarcoma,  follicular  dendritic  cell  sarcomas 
and  Ewing’s sarcoma / PNET. 
HISTOLOGICAL GRADING 
HISTORY 
           The power of histological grading in breast cancer is evident form the 
outset  since  Greenhough  and  a  colleague  reviewed  histological  sections  and 
assessed  eight  morphological  factors  namely,  the  amount  of  gland  formation, 
presence of secretory vacuoles,  cell size,  nuclear size, variation in size of both 
cells and nuclei, degree of nuclear hyperchromatism and number of mitoses and 
allocated  to  one  of  3  grades  grade  –  I  low  malignancy  grade  II  –  medium 
malignancy and grade III – high malignancy. 
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             The next landmark provided by studies carried out by Scarff and his  
colleagues placed most emphasis on amount of tubule formation, inequality in size 
of nuclei,   hyperchromatism and mitosis. 
              Bloom, a radiotherapist revived interest in histological grading. He chose 
to follow the Patey and Scarff method but seem to have paid more attention to 
mitotic figures and found a clear correlation with prognosis.           
               Together with Richardson, a surgical research fellow, Bloom is 
responsible  for  the  next  advance  in  histological  scoring  system.  Scarff  Bloom 
Richardson method was adopted as preferred method by WHO24,26,29. 
                Alternative methods that concentrated on nuclear characteristics such as  
Black’s method has been used almost exclusively in the United States where it is 
referred as nuclear grading24. They devised four grades of malignancy based on the 
regularity of nuclear outline, delicacy of chromatin strands, presence or absence of 
nucleoli and mitotic figures. Black and colleagues reversed the numerical order to 
their grades in comparison to Scarff Bloom Richardson so that nuclear grades 0 –1 
apply to poorly differentiated carcinomas and grades 3 – 4 to well differentiated 
tumours. 
               The method devised by Harveit was based on the definition of cell 
borders, nuclear crowding, nuclear lobulation and nuclear diameter. Mitoses were 
not considered. 
                Fisher and associates combined the histological grade devised by Patey 
and Scarff and nuclear grade. Le Doussal and colleagues confirmed that the SBR 
method together with nodal status were the most important factors in predicting 
metastasis- free survival. They also found the nuclear pleomorphism and mitotic 
count were the most predictive elements. They arranged the scores to produce five 
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modified SBR categories (MSBR) which produced better separation of prognostic 
groups. 
             It can be concluded that selection of particular grading method is to a large 
extent a matter of personal choice. In practice the choice of method till the present 
has emerged mainly along geographical lines,  the nuclear grading technique of 
Black, being more popular in United States and the SBR method in Europe and 
Australia. 
              Elston has been the most vocal champion of this approach to use 
architecture and cytology in conjunction to correlate with prognosis and is usually 
referred to as the Nottingham modification of the Bloom – Richardson system. 
This system also incorporates the evaluation of mitotic activity. 
Preparation of specimen
              The first pre-requisite for accurate histological grading is careful  
specimen preparation.10% phosphate buffered formalin and other fixatives such as 
B5s are used.With a 6hr delay in fixation, the number of mitosis was reduced in 
assigned histological grade. This data insists the importance of incising tumour 
masses in the fresh state immediately after resection. Adequate tumour sampling is 
equally important. At least 3 - 4 blocks should be examined. Sections are to be cut 
4 - 6µm. Nuclear detail is obscured if sections are too thick. 
  Parameters of grading
  Histological  grading  is  therefore  based  on  assessment  of  three 
morphological  features,  tubule  formation,  nuclear  pleomorphism  and  mitotic 
counts 24,29,35,36,52.
               Qualitatively tubular structures must exhibit central lumina. Evaluation  
of nuclear pleomorphism is the least satisfactory element of any grading system. 
For complete accuracy morphometry or image analysis can be used but they are 
expensive, time consuming and impractical for routine diagnostic practice. 
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               In order to introduce degree of objectivity, normal epithelial cells in  
breast  tissues  adjacent  to  tumour  can be  used as  reference  point  for  assessing 
differences in nuclear features Inflammatory cells such as lymphocytes can also be 
used for comparative purposes26. Regarding the assessment of mitotic counts,  a 
hyper chromatic nucleus that indicates individual cell necrosis should be excluded 
from the counts. Confusion with apoptic nuclei and intratumoral lymphocytes can 
be avoided by strict  application of criteria for  prophase nuclei.  The size of  so 
called high power field varies upto six fold from microscope to microscope, hence 
our  counts  should  be  standardized  to  a  defined  field  area.  16,26,35. Using  this 
convention any microscope can be calibrated to produce comparable data. Mitotic 
count evaluated under strict quality control conditions seems to be an accurate and 
feasible prognostic variable. 5.
Microscopic grading of breast carcinoma: 
Nottingham Modification of the Bloom-Richardson system 
Tubule formation 
1 point : Tubular formation in > 75% of the tumor. 
2 points : Tubular formation in 10 to 75% of the tumor. 
3 points : Tubular formations in < 10% of the tumor. 
Note : For scoring tubule formations, the overall appearance of the tumor has to be 
taken into consideration. 
Nuclear pleomorphism 
1 point : Nuclei with minimal variation in size and shape. 
2 points : Nuclei with moderate variations in size and shape. 
3 points : Nuclei with marked variation in size and shape 
Note: the tumor areas having cells with greatest atypia should be evaluated.  For 
Mitotic count 
1,  2  or  3  points,  are  assigned  as  per  the  table  adapted  from  Diagnostic 
Histopathology of Tumours by Christopher D.M Fletcher – 3rd edition.
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TABLE 
ASSIGNMENT OF POINTS FOR MITOTIC COUNTS ACCORDING TO THE 
MICROSCOPE FIELD AREA
Field diameter in mm Number of mitoses corresponding toScore 1 Score 2 Score 3
0.40 Up to 1 5 to 8 9 or more
0.41 Up to 4 5 to 9 10 or more
0.42 Up to 4 5 to 9 10 or more
0.43 Up to 4 5 to 10 11 or more
0.44 Up to 5 6 to 10 11 or more
0.45 Up to 5 6 to 11 12 or more
0.46 Up to 5 6 to 11 12 or more
0.47 Up to 5 6 to 12 13 or more
0.48 Up to 6 7 to 12 13 or more
0.49 Up to 6 7 to 13 14 or more
0.50 Up to 6 7 to 13 14 or more
0.51 Up to 6 7 to 14 15 or more
0.52 Up to 7 8 to 14 15 or more
0.53 Up to 7 8 to 15 16 or more
0.54 Up to 7 8 to 16 17 or more
0.55 Up to 8 9 to 16 17 or more
0.56 Up to 8 9 to 17 18 or more
0.57 Up to 8 9 to 17 18 or more
0.58 Up to 9 10 to 18 19 or more
0.59 Up to 9 10 to 19 20 or more
0.60 Up to 9 10 to 19 20 or more
0.61 Up to 9 10 to 20 21 or more
0.62 Up to 10 11 to 21 22 or more
0.63 Up to 10 11 to 21 22 or more
0.64 Up to 11 12 to 22 23 or more
0.65 Up to 11 12 to 23 24 or more
0.66 Up to 11 12 to 24 25 or more
0.67 Up to 12 13 to 25 26 or more
0.68 Up to 12 13 to 25 26 or more
0.69 Up to 12 13 to 26 27 or more
0.70 Up to 13 14 to 27 28 or more
          Mitotic figures are to be counted only at the periphery of the tumor. 
Counting should begin in the most mitotically active area ; 10 high-power fields 
are to be counted in the same area (but not necessarily contiguous). The fields 
should be filled with as much tumor as possible ; poorly preserved areas are to be 
avoided.  . 
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         Point scoring system was not meant to ascribe mathematical accuracy to the  
method but it is certainly a step on the way to providing greater objectivity in an 
essentially subjective method and for creating reproducible treatment 
algorithms. 5,26.
         The scores for each factor are added together giving a possible total of 3 –9 
points. Tumour grade is then allocated on the following basis. 
3.5 points – grade 1 – well differentiated. 
6-7 points – grade 2 – moderately differentiated. 
8-9 points – grade 3 – poorly differentiated. 
         An acceptable degree of interobserver reproducibility has been achieved 
such that a strict protocol as recommended by Elston and Ellis is followed. 
Significance of grading
         Histologic grading is performed in all cases of invasive carcinoma of breast  
regardless  of  morphological  types29. Special  types  such  as  tubular,  invasive 
cribriform and mucinous carcinoma carry  excellent  prognosis  comparable  with 
their grade I status.26,42. Infiltrating lobular carcinoma especially those of classical 
subtypes are designated grade 2 26,42. However a minority fall into grade 1 or grade 
3 category. By definition medullary carcinomas are considered as grade 3  but 
have  been  found  to  have  a  more  favourable  prognosis  than  this  degree  of 
differentiation would imply  26,42.Grading and typing should be carried out in all 
invasive cancers. 
In the majority of breast carcinomas of special type, the grade does not 
represent  a  prognosis  factor.  Validity  of  grading of  lobular  carcinoma requires 
further  evaluation.  In  lobular  carcinomas,  the  diffuse  distribution  of  tumour 
structures represents the main unfavourable prognostic factor in addition to lymph 
node and pleomorphic cytologic features42.
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           Analysis of a range of prognostic factors using the multiple regression 
technique of Cox showed that only tumour size, histological lymph node status 
and histological grade have significant correlation with overall survival. 
            Based on the co-efficient of significance produced in the Cox analysis, a 
simple composite prognostic index has been devised as follows : 
NPI = 0.2 ×  tumour size + lymph node (1-3) stage + histological grade (1-3)
            The higher the value for NPI, the worse the prognosis. Three groups have 
been identified by employing (arbitrary)cut off points <3.4 for the good prognostic 
group (GPG), 3.41-5.4 for the moderate group (MPG) and >5.4 for the poor group 
(PPG)26.
            NPI has become the most widely used and its strength depends on 
relatively  simple  data,  which  can  be  provided  in  any  routine  histopathology 
laboratory. It is a powerful and reproducible method of assessing prognosis and is 
the only integrated index, which has been confirmed, in prospective studies. In 
future  more  objective  methods  for  estimating  tumour  differentiation  and 
invasiveness  may  become  available,  but  currently  other  techniques  including 
molecular  markers  do  not  achieve  significance  in  multivariate  analysis  when 
compared with histological  grade.  It  is  likely that  a molecular classification of 
breast cancer will only become commonplace when treatment strategies are based 
on specific gene or biological events. 
            Studies on the significance of grading early minimal or stage I breast 
carcinomas  have  generated  controversial  results42. in  contrast  with  the  official 
statement  in  the  WHO book that  tumour  grading has  prognosis  value even in 
breast  cancers  of  1cm  and  smaller.  One  may  criticize  that  the  failure  in 
demonstrating significant results is a consequence of not applying the strict criteria 
of  Elston-Ellis  system.  However  the  report  of  James  et  al  indicates  that  the 
invention of this grading system failed to confirm the prognostic significance of 
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Elston-Ellis  grade in  small  carcinomas.  Thus the  value of  Elston-Ellis  grading 
system seems to be limited to certain subgroups of breast carcinomas. This system 
is not applicable for insitu carcinomas accounting for approximately 10 – 20% of 
breast carcinomas. 
           According to the results of above mentioned studies, the rationale for  
grading tumour smaller than 15mm, which should account for at  least  50% of 
invasive  carcinomas  in  a  screened  population  according  to  the  current 
mammography  screened  quality  assurance  guidelines  may  be  questioned. 
Carcinomas larger than 15mm should be graded with exception of tumours with 
predefined grade as mentioned above42.
           Grading of tumours exhibiting metastasis  at the time of diagnosis may also 
be questioned, as metastasis may be a more significant determinant of the outcome 
than the grade itself. Thus grading seems to be meaningful in approximately one-
third  cases  of  breast  carcinoma;  the  large.  “Not  otherwise  specified”  ductal 
carcinomas.             
IMMUNOHISTOCHEMISTRY 
           Immunohistochemistry is useful in breast tumours in two main sections.  
First, dealing with antibodies it is useful in diagnosis and recognition of various 
conditions. Secondly it  presents an overview of markers which can be used as 
predictive or prognostic markers in breast cancer. 
DIAGNOSTIC  MARKERS
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            The tumour cells show reactivity for low molecular weight Keratin – cyt 8, 
18,  19,  EMA,  antigen  obtained  from  human  milk  fat  globule  membrane  and 
lactalbumin. CEA, B72.3 and BCA 225 are positive in majority of cases. 
Identification of myo-epithelial cells  in combination with luminal epithelial cells 
is generally regarded as benign breast conditions. 
The myoepithelial  cell  markers are smooth muscle actin (SMA),  S100 protein, 
calponin, caldesmin, smooth muscle myosin and cytokeratins 5, 6, 14 33.
• Distinguishing insitu from invasive carcinoma by using antibodies to myo-
epithelial cell markers and  basement membrane proteins (eg. Type IV 
collagen, Laminin). 
• Encapsulated papillary carcinoma is distinguished from intracystic papillary 
carcinoma by using myoepithelial cell markers 37
• To identify neuroendocrine differentiation using neuron specific enolase, 
chromogranin and synaptophysin. 
• Evaluation of spindle cell lesions (metaplastic Vs mesenchymal lesion) by 
using antibodies to cytokeratin and mesenchymal markers (eg. Vimentin, 
CD 34).
• Distinguishing ductal from lobular insitu carcinomas by using antibodies to 
E.cadherin. 
• Assessment  of  metastatic  lesions  for  possible  breast  origin  by  using 
antibodies  to  estrogen  receptor,  gross  cystic  disease  fluid  protein, 
cytokeratin 7, 20 and other markers depending on clinical circumstances, 
anatomic location and histological differential diagnosis 52.
Cell  adhesion  molecules  such  as  integrins,  cadherins,  proteases, 
metalloproteinases, growth factors and their receptors, tumour suppressor genes 
such as P53, oncogene expression including C-erb B-2 status have been 
assessed 16.
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     Steroid hormone receptors such as oestrogen and progesterone receptors are 
also assayed . They predict response to hormonal therapy . Likewise expression of 
c-erb-2 protein predicts the response to chemotherapy using monoclonal antibody 
trastuzumab (Herceptin)33.
PROLIFERATIVE INDICES 
            Proliferative  rate  of  tumour  can  be  determined  by  combining  
measurements of growth fraction and cell cycle time through sequential sampling. 
Estimate of S-phase fraction with thymidine or 5 Bromodeoxy uridine labeling 
tests and other growth fraction markers such as MIB/Ki-67 and proliferating cell 
nuclear  antigen  (PCNA)  or  cyclin  has  emerged  33.Quantitation  of  KI-67  in 
CAPSS(Columnar Cell Alteration with Prominent Apical Snouts and Secretions) 
has  increased  compared  with  normal  breast  but  lower  than  insitu  or  invasive 
cancer. 
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OBSERVATION AND RESULTS 
This prospective study of breast neoplasms cover a total of 267 cases in which 
120 cases were observed as benign neoplasms and 147 cases as malignant neoplasms.
The incidence of breast neoplasms from January 2005 to December 
2006 in correlation with total number of specimens – females is given in 
following table 1. 
TABLE . 1
INCIDENCE OF BREAST NEOPLASMS
S.No. Period Total No. of Female Neoplasm
No. of Breast 
Neoplasm Percentage
1. Jan 2005 – Jun 2005 333 69 20.72 %
2. Jul 2005 – Dec 2005 316 68 21.51 %
3. Jan 2006 – Jun 2006 221 50 22.62 %
4. Jul 2006 – Dec 2006 247 80 32.38 %
TOTAL 1117 267 24.30%
The overall incidence of breast neoplasm is 24.30%
Then considering the incidence of malignancies alone, the overall percentage of 
breast malignancies is 17.50% as given in following table  2. 
TABLE . 2
INCIDENCE OF BREAST MALIGNANCIES 
S.No. Period Total No. of Female Neoplasm
No. of Breast 
Neoplasm Percentage
1. Jan 2005 – Jun 2005 237 38 16.05 %
2. Jul 2005 – Dec 2005 274 41 14.96 %
3. Jan 2006 – Jun 2006 166 31 18.67 %
4. Jul 2006 – Dec 2006 177 36 20.33 %
TOTAL 854 146 17.50%
When age specific incidences are divided into eight groups (i.e. <10yrs to > 
70yrs),there was an increased incidence of breast neoplasms observed in 
31-50yrs (116 cases, 43.44%) followed by 10-20yrs (54cases, 20.22%) and 
21-30yrs (53cases, 19.85%). The incidence is very low in paediatric age 
group less than 10yrs (1case, 0.37%) followed by 61-70yrs (8cases, 2.99%) 
as given in following table 3. 
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TABLE . 3
AGE INCIDENCE OF BREAST NEOPLASMS
S.No. Age Group No. of Cases Percentage
1. <10yrs 1 0.37 %
2. 10 – 20yrs 54 20.22 %
3. 21 – 30yrs 53 19.85 %
4. 31 – 40yrs 58 21.72 %
5. 41 – 50yrs 58 21.72 %
6. 51 – 60yrs 35 13.10 %
7. 61 – 70yrs 8 2.99 %
8. >70yrs – –
Like, age specific incidences of malignant neoplasms are given in following Table 4
TABLE . 4.
S.No. Age Groups Epithelial Fibroepithelial Mesenchymal Lymphoma
1. < 20yrs 1 – – –
2. 21 – 30yrs 9 – – –
3. 31 – 40yrs 39 2 2 –
4. 41 – 50yrs 47 3 – 1
5. 51 – 60yrs 31 1 1 –
6. 61 – 70yrs 9 – – –
The table shows, like overall incidence, the incidence of malignant neoplasms are 
also common between 41 – 50yrs (51cases, 34.93%) followed by 31 – 40yrs (43cases, 
29.45%) and 51 – 60yrs (33cases, 22.60%). 
Most of the females with lump breast detected by routine clinical examination 
were from the surrounding villages with low socio economic status. They presented with 
the following symptoms as given in table 5. 
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TABLE . 5
CLINICAL EVALUATION OF CASES WITH MALIGNANT TUMOURS
S.No. History / Clinical Features No. of cases Percentage
1. Early menarche 140 95.89 %
2. Age of first child birth 
Early 137 93.83 %
Late 9 6.16 %
3. Parous women 141 96.57 %
4. Nulliparous women 5 3.42 %
5. Breast fed 141 96.57 %
6. Menstrual status
Menopausal 93 63.69 %
Menstruating 53 36.30 %
7. Family history 4 2.73 %
8. Treatment history
Hormonal therapy 0 0 %
Previous biopsy for benign disease 2 1.36 %
9. Breast lump 146 100 %
10
.
Discharge
60 41.09 %
11
.
Skin changes
Erythema 31 21.23 %
Peaude orange appearance 46 31.50 %
Ulceration 19 13.01 %
12
.
Nipple retraction
40 27.39 %
13
.
Axillary nodes
45 30.82 %
14 Location 
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Upper outer quadrant
Upper inner quadrant
Lower outer quadrant
Lower inner quadrant
Diffuse – involving all quadrants
85
11
8
6
36
58.21 %
7.53 %
5.47 %
4.10 %
24.65 %
All the cases presented with breast lump (146 cases, 100%) and the risk factor 
like early menarche was seen in most cases. Most of the women were multiparous with 
history  of  regular  breast  feeding.  Skin  changes  like  erythema,  peau-de-orange 
appearance,  erosion/ulceration  of nipple,  nipple retraction  were seen in one fourth of 
cases. The table also shows most of the neoplasms were observed in the upper outer 
quadrant followed by diffuse involvement and upper inner quadrant. The neoplasms were 
rarely  seen  in  lower  outer/inner  quadrant.  Axillary  Lymphadenopathy  and  nipple 
discharge were also observed in a proportion of cases. 
The overall distribution of breast neoplasms is given in the following table 6. 
TABLE . 6
DISTRIBUTION OF BREAST NEOPLASMS
S.No. Type of Neoplasm No. of Cases Percentage
1. Benign 120 44.94 %
2. Insitu 0 0 %
3. Invasive with insitu 12 4.49 %
4. Epithelial tumours 124 46.44 %
5. Fibroepithelial tumours 7 2.24 %
6. Mesenchymal tumours 3 1.12 %
7. Lymphoma 1 0.37 %
 
Malignant neoplasm predominates with 147 cases (54.66%) when compared with 
benign neoplasms (120 cases, 45.31%)
The associated features – Proliferative and nonproliferative changes observed in 
received specimens are presented in the following table 7. 
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TABLE . 7
S.No. Histopathological changes No. of cases
1. Non Proliferative breast changes
a) Duct ectasia 0
b) Cysts 4
c) Apocrine change 0
d) Mild hyperplasia 6
e) Adenosis 4
f) Fibroadenoma without complex features 107
2. Proliferative disease without atypia 
a) Moderate or florid hyperplasia 10
b) Sclerosing adenosis 5
c) Papilloma 1
d) Radial scar –
e) Fibroadenoma with complex features –
3. Proliferative disease with atypia
a) Atypical ductal hyperplasia 1
b) Atypical lobular hyperplasia 0
4. Carcinoma  Insitu
a) Lobular carcinoma insitu 0
b) Ductal carcinoma insitu 0
5. Other Neoplasms
a) Tubular adenoma 2
b) Lactating adenoma 1
c) Nipple adenoma 1
d) Myofibroblastoma 1
e) Adenomyoepithelioma 1
f) Duct papilloma 1
Conventional fibroadenoma(Fig7-10&24) without complex features predominates 
with 107 cases. Florid hyperplasia was observed in 10 cases and sclerosing adenosis in 5 
cases. 
The epithelial  and stromal changes in fibroadenoma are given in the following 
table 8.
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TABLE . 8
S.No. Histopathological changes No. of cases
1. Pattern
1) Pericanalicular 60
2) intracanalicular 35
3) Both 12
2. Epithelial changes
1) Mild hyperplasia 6
2) Moderate to florid hyperplasia 10
3) Atypical ductal hyperplasia 1
4) Sclerosing adenosis 5
5) Adenosis 4
6) Cystic change 4
7) Apocrine change –
3. Connective tissue (stromal) change
1) Increased cellularity 13
2) Hyalinisation 13
3) Myxoid changes 16
The age incidences of individual benign neoplasms are given in following table 9. 
TABLE . 9
INCIDENCES OF INDIVIDUAL BENIGN NEOPLASMS
S.No. Type of benign neoplasm
Age Groups
< 20 21 – 30 31 – 40 41 – 50 51 – 60
1. Fibroadenoma 53 56 13 3 2
2. Fibroadenoma with 
benign phyllodes 1 3 – – –
3. Benign phyllodes – – 1 1 –
4. Others 
a) Nipple adenoma – 1 – – –
b) Tubular adenoma 1 1 – – –
c) Lactating adenoma – 1 – – –
d) Myofibroblastoma – – – 1 –
e) Duct papilloma(Fig13) – – 1 – –
f) Adenomyoepithelioma – – – – 1
Most of the fibroadenomas are seen in the early reproductive age group, less than 
20yrs  (53  cases,  50%) followed  by 21  –  30yrs  (36cases,  33.96%).  Special  forms  of 
adenomas  such  as  tubular  adenoma(Fig.11)  and  lactating  adenoma(Fig.12)  were  also 
observed  in  the  same  age  group.  One  case  of  adenomyoepithelioma  and 
myofibroblastoma were observed in the postmenopausal age group. 
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Distribution of epithelial / Non epithelial malignant neoplasms of the breast are 
given in the following tables 10A and 10b. 
TABLE 10A
DISTRIBUTION OF EPITHELIAL MALIGNANT TUMOURS
S.No. Type of tumour No. of cases
1. Infiltrating  ductal  carcinoma  (IDC)  with  ductal 
carcinoma insitu (DCIS) 12
2. Infiltrating ductal carcinoma – NOS 103
3. Invasive lobular carcinoma(Fig.26) 2
4. Mucinous carcinoma(Fig.2,18&19) 4
5. Medullary carcinoma(Fig.25) 1
6. Invasive papillary carcinoma(Fig.20&21) 5
7. Invasive micropapillary carcinoma(Fig.22) 1
8. Infiltrating cribriform carcinoma(Fig.29) 1
9. Adenoid cystic carcinoma(Fig.27) 1
10. Neuroendocrine – carcinoid tumour(Fig.28) 1
11. Metaplastic carcinoma(Fig.30-32) 4
12. Adenomyoepithelioma  with  malignancy  (epithelial) 
(Fig.33&34) 1
TABLE 10B
DISTRIBUTION OF NON-EPITHELIAL MALIGNANT TUMOURS
Type of tumour No. of cases
  Mesenchymal
     Pleomorphic sarcoma 1
     Fibrosarcoma 1
     Angiosarcoma(Fig.3) 1
  Lymphoma
     Non Hodgkin’s Lymphoma 1
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Most of the cases were infiltrating ductal carcinoma-NOS type(Fig.1) followed by 
IDC with DCIS(Fig.17). 5 cases of invasive papillary carcinoma and 4 cases of mucinous 
and metaplastic carcinoma were also observed. In our study 4 nonepithelial malignant 
neoplasms  such  as  i.e.  pleomorphic  sarcoma(Fig.43),  fibrosarcoma(Fig.44), 
angiosarcoma (Fig.45)and lymphoma(Fig.46&47) were also observed.
         
The histomorphological patterns seen in DCIS are given in the following table 11. 
TABLE .11
HISTOPATHOLOGICAL PATTERNS IN DCIS ASSOCIATED WITH IDC.
S.No. HPE Pattern No. of Cases
1. Solid 3
2. Comedo 8
3. Micropapillary 1
4. Cribriform 2
Comedopattern with or without necrosis(Fig.23)is seen in 8 cases 
followed by solid pattern in 3 cases. 
            The histopathological pattern in infiltrating ductal carcinoma is given in following 
table 12. 
TABLE .12
HISTOPATHOLOGICAL PATTERNS IN IDC
S.No. HPE Pattern No. of Cases
1. Solid(Fig.16) 27
2. Trabecular(Fig.15) 65
3. Tubular(Fig.14) 7
4. Comedo 23
5. Cribriform 2
6. Papillary –
The trabecular  pattern is  commonly seen (65cases,  56.52%) followed by solid 
(27cases, 23.47%) and comedo pattern (23cases, 20%)
The following table 13 shows the distribution of fibroepithelial lesion. 
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TABLE .13
DISTRIBUTION OF FIBRO-EPITHELIAL TUMOURS
S.No. Type of tumour No. of cases
1. Fibroadenoma
- Nos
- Juvenile
103
4
2. Benign Phyllodes(Fig.4&35) 2
3. Phyllodes with fibroadenoma 4
4. Borderline phyllodes 1
5. Malignant phyllodes(Fig.36&37) 4
6. Malignant phyllodes with heterologous 
differentiation(Fig.5,6,38&42) 2
The age specific grading of malignant neoplasms of breast is given 
in following table 14. 
TABLE. 14
GRADING AND AGE
S.No. Age Groups Grade I Grade II Grade III
1. < 25 – 1 2
2. 25 – 29 – 1 1
3. 30 – 34 – 8 2
4. 35 – 39 2 12 6
5. 4 0 – 44 – 15 7
6. 45 – 49 2 21 8
7. 50 – 54 2 14 1
8. 55 – 59 3 8 1
9. 60 – 64 2 10 4
10. 65 – 69 2 3 1
11. ≥  70 – – 1
13 (9.2%) 93 (66.42%) 34 (24.28%)
Like, the nodal positivity and staging are given in following table15A 
and 15B. 
42
TABLE .15A
AGE AND NODAL POSITIVITY
S.No. Age Groups No. of Nodes1 – 3 4 – 9 ≥  10
1. < 25 – – –
2. 25 – 29 1 – –
3. 30 – 34 4 1 –
4. 35 – 39 5 1 –
5. 40 – 44 6 2 –
6. 45 – 49 2 2 –
7. 50 – 54 4 2 –
8. 55 – 59 3 1 –
9. 60 – 64 5 3 –
10. 65 – 69 2 – –
11. ≥  70 – – –
TABLE .15B
STAGING AND GRADING
S.No. Stage Grade I Grade II Grade III
1. Stage I – 3 –
2. Stage II A 5 38 16
Stage II B 7 32 9
3. Stage III A – 13 3
Stage III B – 1 1
4. Stage IV – – –
The  overall  grading  of  epithelial  tumours  according  to  modified  Bloom  and 
Richardson Method. Elston & Ellis is given in the following table 16.  
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TABLE .16
GRADING OF EPITHELIAL TUMOURS – MODIFIED BLOOM & 
RICHARDSON METHOD – ELSTON & ELLIS
S.No. HPE No.
Scores
Total 
Score Grade
Tubule and 
Glandular 
formation
Nuclear 
pleomorphism
Mitotic 
counts
1. 24/05 1 2 1 4 I
2. 52/05 3 2 1 6 II
3. 96/05 3 2 1 6 II
4. 124/05 3 2 1 6 II
5. 166/05 3 2 1 6 II
6. 195/05 3 2 1 6 II
7. 295/05 3 2 1 6 II
8. 345/05 3 2 1 6 II
9. 347/05 3 2 2 7 II
10. 352/05 3 2 1 6 II
11. 433/05 3 2 3 8 III
12. 505/05 3 2 1 6 II
13. 530/05 3 2 1 6 II
14. 533/05 3 2 1 6 II
15. 538/05 3 2 1 6 II
16. 559/05 3 3 2 8 III
17. 627/05 3 2 1 6 II
18. 663/05 3 2 1 6 II
19. 749/05 3 2 1 6 II
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20. 765/05 3 2 1 6 II
21. 816/05 3 3 3 9 III
22. 859/05 3 2 1 6 II
23. 881/05 3 2 1 6 II
24. 917/05 3 3 1 7 II
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S.No. HPE No.
Scores
Total 
Score Grade
Tubule and 
Glandular 
formation
Nuclear 
pleomorphism
Mitotic 
counts
25. 1055/05 3 2 1 6 II
26. 1068/05 3 2 1 6 II
27. 1098/05 3 2 1 6 II
28. 1101/05 3 2 1 6 II
29. 1104/05 3 3 2 8 III
30. 1174/05 3 3 1 7 II
31. 1228/05 3 3 1 6 II
32. 1344/05 3 2 1 6 II
33. 1352/05 3 2 2 7 II
34. 1359/05 3 2 1 6 II
35. 1501/05 3 2 1 6 II
36. 1505/05 3 2 3 8 III
37. 1654/05 3 2 1 6 II
38. 1772/05 2 2 1 5 I
39. 1783/05 3 2 1 6 II
40. 1805/05 3 2 1 6 II
41. 1820/05 3 3 2 8 III
42. 1886/05 3 2 1 6 II
43. 1970/05 3 2 1 6 II
44. 1972/05 3 2 1 6 II
45. 2091/05 3 2 1 6 II
46
46. 2111/05 3 2 1 6 II
47. 2174/05 3 2 1 6 II
48. 2204/05 3 2 1 6 II
49. 2264/05 3 3 2 8 III
50. 2216/05 3 2 1 6 II
51. 2319/05 3 3 2 8 III
52. 2362/05 3 3 2 8 III
53. 2401/05 3 2 1 6 II
54. 2455/05 3 2 1 6 II
55. 2496/05 3 2 1 6 II
56. 2497/05 3 2 1 6 II
57. 2540/05 3 2 2 7 II
58. 2541/05 3 2 2 7 II
59. 2788/05 3 2 1 6 II
60. 2801/05 3 2 1 6 II
61. 2817/05 3 2 1 6 II
62. 3035/05 3 2 2 7 II
63. 26/06 3 2 2 7 II
64. 129/06 3 2 1 6 II
65. 324/06 3 2 1 6 II
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S.No. HPE No.
Scores
Total 
Score Grade
Tubule and 
Glandular 
formation
Nuclear 
pleomorphism
Mitotic 
counts
66. 386/06 3 2 1 6 II
67. 400/06 3 2 1 6 II
68. 475/06 3 2 1 6 II
69. 481/06 3 2 1 6 II
70. 555/06 3 3 2 8 III
71. 608/06 3 2 3 8 III
72. 753/06 3 3 3 9 III
73. 770/06 3 3 2 8 III
74. 931/06 3 2 1 6 II
75. 1041/06 3 2 2 7 II
76. 1114/06 3 2 1 6 II
77. 1160/06 3 2 1 6 II
78. 1207/06 3 2 3 8 III
79. 1268/06 3 2 1 6 II
80. 1464/06 3 3 2 8 III
81. 1499/06 3 3 2 8 III
82. 1618/06 3 3 2 8 III
83. 1645/06 3 3 2 8 III
84. 1682/06 3 3 2 8 III
85. 1710/06 3 2 1 6 II
86. 1732/06 3 3 2 8 III
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87. 1785/06 3 2 1 6 II
88. 1902/06 3 2 1 6 II
89. 1938/06 3 2 1 6 II
90. 1939/06 3 3 2 8 III
91. 1988/06 3 2 1 6 II
92. 2104/06 3 2 1 6 II
93. 2131/06 1 2 1 4 I
94. 2147/06 3 2 3 8 III
95. 2314/06 3 3 2 8 III
96. 2355/06 3 2 1 6 II
97. 2412/06 3 2 1 6 II
98. 2449/06 3 3 2 8 III
99. 2455/06 3 3 2 8 III
100
.
2497/06
3 2 1 6 II
101
.
2538/06
3 3 2 8 III
102
.
2575/06
3 3 1 7 II
103
.
2643/06
3 2 1 6 II
104
.
2659/06
2 2 1 5 I
105
.
2666/06
3 3 2 8 III
106 2799/06 2 2 1 5 I
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S.No. HPE No.
Scores
Total 
Score Grade
Tubule and 
Glandular 
formation
Nuclear 
pleomorphism
Mitotic 
counts
107
.
2815/06
3 2 1 6 II
108
.
2890/06
3 2 1 6 II
109
.
2996/06
3 2 1 6 II
110
.
3105/06
3 2 1 6 II
111
.
3106/06
3 2 1 6 II
112
.
3126/06
3 2 1 6 II
113
.
3128/06
3 3 2 8 III
114
.
3360/06
2 2 1 5 I
115
.
3361/06
3 2 1 6 II
The  grading  for  epithelial  special  types,  nonepithelial  neoplasms  as  well  as 
Malignant Phyllodes tumour are given in the following tables 17A, 17B and 18 
TABLE .17A
GRADING OF SPECIAL TYPES – EPITHELIAL
S.No. HPE No. Diagnosis
Tubule and 
Glandular 
formation
Nuclear 
pleomorphism
Mitotic 
counts
Total 
Score Grade
1. 295/05 Metaplastic 
carcinoma 3 3 2 8 III
2. 794/05 Invasive  lobular 3 2 1 6 II
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carcinoma 
3. 1745/06 Invasive 
papillary 
carcinoma
3 2 1 6 II
4. 1933/05 Papillary 
carcinoma  with 
cystic changes
3 2 1 6 II
5. 2405/05 Metaplastic 
carcinoma 3 3 2 8 III
6. 2469/05 Mucinous 
carcinoma 3 1 1 5 I
7. 2471/05 Infiltrating 
cribriform 
carcinoma
3 1 1 5 I
8. 2898/05 Adenoid  cystic 
carcinoma 3 2 1 6 II
9. 2909/07 Invasive  lobular 
carcinoma 3 2 1 6 II
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S.No. HPE No. Diagnosis
Tubule and 
Glandular 
formation
Nuclear 
pleomorphism
Mitotic 
counts
Total 
Score Grade
10. 3027/05 Intracystic papillary 
carcinoma 3 2 1 6 II
11. 3076/05 Invasive papillary 
carcinoma 3 2 1 6 II
12. 3085/05 Metaplastic carcinoma 3 3 2 8 III
13. 545/06 Invasive 
micropapillary 
carcinoma
3 2 1 6 II
14. 695/06 Medullary carcinoma 3 2 3 8 III
15. 732/06 Mucinous carcinoma 3 1 1 5 I
16. 1106/06 Invasive papillary 
carcinoma 3 2 1 6 II
17. 1876/06 Metaplastic carcinoma 3 3 2 8 III
18. 1965/06 Mucinous carcinoma 3 1 1 5 I
19. 2670/06 Adenomyoepithelioma 
with malignancy 3 2 1 6 II
20. 2774/06 Mucinous carcinoma 3 1 1 5 I
21. 987/06 Neuro endocrine 
tumour 3 1 1 5 I
TABLE .17B
GRADING OF NON-EPITHELIAL TUMOURS
S.No. HPE No. Diagnosis Grade
1. 801/05 Non Hodgkin’s Lymphoma II
2. 2281/05 Fibrosarcoma II
3. 3013/05 Pleomorphic sarcoma III
4. 916/06 Angiosarcoma I
When grading the  epithelial  tumours,  tubule  and glandular  formation,  nuclear 
pleomorphism and mitotic counts were included for scoring. 
EPITHELIAL  TUMOURS  WITH  SCORE  3  –  5  WERE  GRADED  AS 
GRADE I, 6 – 7 AS GRADE II AND 8 – 9 AS GRADE III. 
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TABLE. 18
S.No. Features Case I764/05
Case 2
1475/05
Case 3
802/06
Case 4
983/06
Case 5
2195/06
Case 6
1028/06
1. Stromal 
Hypercellularity Moderate Marked Marked Marked Moderate Marked
2. Cellular 
pleomorphism Marked Moderate Marked Marked Marked Marked
3. Mitosis > 8/hpf > 7/hpf > 10hpf 7/hpf 6/hpf > 10/hpf
4. Margins Pushing/ intermediate
Pushing/ 
Intermediate Invasive Invasive
Pushing/ 
Intermediate Invasive
5. Stromal pattern Stromal expansion
Stromal 
overgrowth
Stromal 
overgrowth
Stromal 
expansion
Stromal 
expansion
Stromal 
overgrowth
6. Heterologous stromal 
differentiation – – + – – +
In phyllodes tumour, morphological factors such as stromal hypercellularity, cellular pleomorphism, mitosis, margins, stromal 
pattern and Heterologous stromal differentiation were taken for scoring.
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DISCUSSION
          Breast cancer is the commonest cancer among females in developed  
countries. It is the second most common cancer among women in south India but 
it  is  the  most  frequent  cancer  among women in  western  India  (Bombay)15.  In 
several countries worldwide, there has been a steady increase in breast cancer.
There is a wide variation in incidence between countries, and also within 
any country for which several causes are cited. Some of the increased diagnosis is 
due  to  more  widespread  screening  programmes  and  alterations  in  registration 
procedures in certain countries, but it appears that there is a genuine increased 
incidence not accounted for by these factors1. These two aspects of breast cancer 
emphasize the importance of early diagnosis and appropriate management.
             
               The incidence as well as prevalence of breast cancer by various studies  
conducted as per the literature and journals are given in the following table no 19.
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TABLE. 19
S.No. Name and Year of Study Prevalence of Breast Cancers
1. Indian Cancer Society, Mumbai (2001-2003) 27.47%
2. Kidwai Memorial Institute of Oncology, 
Bangalore (2001-2003)
24.58%
3. Nargis Dutt Memorial Cancer Hospital, Barshi 
(2001-2003)
16.85%
4. Gandhi Medical College, Bhopal (2001-2003) 24.91%
5. Gujarat Cancer and Research Institute, 
Ahamadabad (2001-2003) 
19.32%
6. Dr. B.R. Ambedkar Institute Rotary Cancer 
Hospital, All India Institute of Medical 
Sciences, New Delhi. (2001-2003)
25.11%
7. National Cancer Registry, Bangalore 
Dibrugarh District (2003-2004)
18.78%
8. National Cancer Registry, Bangalore 
Kamrup Urban District (2003-2004)
18.6%
9. National Cancer Registry, Bangalore 
Silchar town (2003-2004)
16.5%
10. National Cancer Registry, Bangalore 
Imphal West District (2003-2004)
14.3%
11. National Cancer Registry, Bangalore 
Mizoram State (2003-2004)
11.9%
12. National Cancer Registry, Bangalore
Sikkim State (2003-2004)
14.2%
13. WHO, Annual Report 2002 20%
14. Cancer Institue (WIA), Adyar Chennai (2001-
2003)
26.07%
15. Study of Thanjavur Medical College Hospital 
(2002 -2003)
12.3%
16. Present Study 17.50%
In our study the prevalence is 17.50%, which is in close correlation with 
other studies as well as the annual report by WHO. The table also shows that the 
prevalence at  Mumbai is  27.47%, which denotes  breast  cancer  being the  most 
common malignant neoplasm in females surpassing carcinoma cervix. The table 
also shows that  the  incidence at  semi-urban area-Thanjavur medical  college is 
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increasing from 12.3% to 17.50%, which is about 40%. This study also shows that 
in females, breast neoplasms alone constitute 25%.
The age specific incidence of breast neoplasm ranges from 20-70 yrs as per 
the  studies,  journals  and  literature  which  also  show  increased  incidence  at 
postmenopausal  age group i.e.  50-70 yrs.  In  contrast,  in  our  study the  highest 
incidence of breast neoplasms are noticed between 21-50 yrs and the incidence of 
breast  neoplasms  after  60yrs  constitute  less  than  3%.  Like,  the  age  specific 
incidences  of  malignant  neoplasms  are  also  common  between  40-50  yrs  in 
contrast.  Our  study  also  shows  that  incidence  of  epithelial  neoplasms  (94%) 
outnumber the mesenchymal neoplasms.
The risk factor evaluation shows that presence of breast  lump and early 
menarche are found in almost all cases but in contrast to the literature most of 
them are multipara and with early age at first child birth. Most of the neoplasms 
are  found in the upper outer quadrant which is in correlation with literature.
Studies in Nordic countries have shown an increased breast cancer risk in 
women  of  low parity  and  those  who  have  their  first  child  late28,  which  is  in 
contrast to our study. Likewise in studies in Norway it has been found that high 
parity is associated with an overall reduced risk of breast cancer but in our study 
parous women contribute to 96.57% of malignant breast tumour cases. Similarly 
in  Norway studies,  the  protective  effect  of  high parity  was  particularly  strong 
among women with first child birth before age of 20 years and rather weak among 
those with first child birth at the age 30 years or more28. This is in contrast to our 
study where early age at first child birth contributes to 93.83% of cases and late 
age at first birth to only 6.16% of cases.
Studies  in  Nordic  countries  and  Norway  have  shown  increased  risk  of 
breast  cancer  among  women  who  had  oral  contraceptives  and  hormone 
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replacement  therapy  for  prolonged  periods  but  in  contrast,  our  study  has  no 
association with the above mentioned risk factors28.
Nipple discharge is considered to be pathologic, if it is spontaneous, arises 
from a single duct, is persistent and contains gross or occult blood. As per the 
studies by Richard J.Santen et al, among female patients referred to physicians 
because of symptoms of breast disorder, 6.8% have nipple discharge50. This is in 
contrast with our study where 41.09% of cases presented with nipple discharge.
Among  women  who  have  had  a  benign  breast  biopsy,  the  risk  for 
developing  subsequent  carcinoma  is  related  to  the  histologic  components  of 
antecedent biopsy. A higher relative risk is associated with atypical hyperplasia 
than with other proliferative lesions. Page et al found the relative risks to be 4.7 
and 5.8 respectively for women with atypical duct and atypical lobular hyperplasia 
when compared with women who had non proliferative biopsies12. In our study 
women who had previous biopsy for benign disease account for 1.36% of cases 
but  relevant  details  about  histologic  components  of  antecedent  biopsy  are  not 
available.
The interaction of atypical hyperplasia with family history is so strong in 
the study of  David L.  Page et  al54,  that  it  is  relevant  to  consider women with 
atypical hyperplasia who have a family history of breast cancer separately from 
those who do not. Women with a positive family history experienced a risk of 
invasive breast cancer of about 20% at 15 years. This strong interaction has been 
supported in two recent studies18. In our study family history contributes to 2.73% 
of cases but in contrast no interaction of atypical hyperplasia is found.           
In our study, benign neoplasms constitute 45% of cases with predominantly 
fibroadenoma exhibiting conventional  pattern without  complex features.    Few 
cases of non-proliferative breast changes i.e hyperplasia and cystic changes are 
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also observed in this study. As in the literature precancerous lesions like sclerosing 
adenosis and florid hyperplasia are also observed in this study.
      Most of the cases with benign breast neoplasms presented as  nontender,  firm,  
mobile  masses   varying  in  size   from 1  to  15  cms.   Almost   all  cases   are 
evaluated  initially  with fine needle  aspiration and  subsequently  subjected for 
excision  biopsy.
Fine needle aspiration remains   as a single initial evaluative tool in breast 
lump with sensitivity and specificity of 90 to 95%.
The major  goals in evaluation  of breast biopsy is to distinguish  benign 
from insitu,  invasive  breast cancers  and to assess the risk of  subsequent  breast 
cancer  associated with benign lesions  identified.
The  benign  disorders  are  categorized according to the criteria of  Dupont 
Page and Rogers as  Nonproliferative diseases,   proliferative  diseases without 
atypia and  proliferative  diseases with  atypia 60 Dupont  and page  quantified   the 
association between subtypes of  benign breast  disease  and breast  carcinoma. 
They have  observed that  the  risk is  minimal   for   non-proliferative   disease, 
modestly  increased  for proliferative disease  without  atypia and greatest  for 
atypical-hyperplasia  18. Women  with   nonproliferative   lesion  associated  with 
strong family history  are also  at increased  risk.  
According to Timothy W.Jacobs et al, for women with proliferative  disease 
without atypia  the  relative   risk of breast  cancer is 3.0 for those with  radial 
scars and 1.5  for those without radial  scars.   Among  women with  atypical 
hyperplasia  the relative  risk for  breast  cancer  is 5.8  for those with  radial scars  
and 3.8 for those without  radial scars.57 David L  page et al also pointed out that 
women with atypical lobular  hyperplasia associated with family history have  the 
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relative risk of  8.4 and those with  atypical  ductal hyperplasia and family  history 
have the relative  risk of 9.7 23..
In  fibroadenomas,  the  morphological   patterns  i.e.  pericanicular, 
intracanalicular  and mixed  fashions   are  observed  even though  they have little 
importance  in prognosis of the  patient.  According to the  criteria of  Page et al,  
the risk of  breast  cancer  after benign disease is slightly  elevated in the presence 
of  proliferative  disease without  atypia and is substantially increased  in women 
with  atypical hyperplasia.  The magnitude of  the association between  atypical 
hyperplasia  and risk  of breast cancer (RR 3.7)  is in the range  reported  by 
Dupont and Page (RR, 5.3)  and Carter  et al (RR - 3.0).18  Epithelial   changes like 
florid  hyperplasia and sclerosing   adenosis are also  followed  up for a period of  
2 years and no evidence  of malignant  transformation  are  observed  in this study.  
As in the literature as well as  studies by various resource   people,  fibroadenoma 
is commonly  observed in the age group of  15-30 years in our  study.
As a result of population - based  mammographic  screening , the panorama 
of the diagnosed breast  carcinomas has shifted  from the  clinically detectable 
advanced  tumours to the clinically  silent but radiologically  detectable  early 
forms of  breast  cancer  in most of the  developed  countries.  A  reduction in 
breast  cancer  mortality has been achieved.42.  
In our study infiltrating ductal  carcinoma NOS,  type    observed  in 103 
cases  stands as the most  common malignant  neoplasm  of the breast.   15%  of 
the cases  also show  associated  DCIS  changes.  In our  study,  the epithelial 
malignant   neoplasms  predominates  with   136   cases,   50.93%.   Few  rare 
neoplasms  like  invasive  lobular  carcinoma,  medullary carcinoma,  mucinous 
carcinoma,  invasive  papillary  carcinoma,  invasive  micropapillary  carcinoma, 
infiltrating  cribriform cardinoma,  Adenoid  cystic  carcinoma,  Neuro-endocrine - 
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carcinoid  tumour and  metaplastic  carcinoma  are  also observed  in this study. 
One   case  of  adenomyoepithelima  with  epithelial  malignant   transformation 
exhibited   as  epithelial  cells  dispersed  in  solid  sheets   with  absence  of  myo-
epithelial  layer  and  the   individual  cells  having  increased   nuclear    atypia 
accompanied  by  atypical  mitosis  is also  observed  in this study.  
In  our   study   4  cases   of   non-epithelial  malignant   tumours  are  also 
observed.   Pleomorphic   sarcoma   in  which    the  neoplastic   cells   are 
undifferentiated  small cells admixed with  bizarre cells are  dispersed in solid 
sheets.   There   is  increased   atypical  mitosis  and   areas  of  necrosis.   In 
fibrosarcoma   the  individual  cells  are   spindle  cells  arranged  in  the  form  of 
herring  bone  pattern.   Angiosaroma  consists  of   interanastamosing  vascular 
channels  dissecting  the interlobular  stroma and some  replacing  the terminal 
ductal  lobular  units.  The  nuclei of the  endothelium  lining the  neoplastic 
vessels  are  prominent  and  hyperchromatic.  Primary   breast  lymphoma  is a 
rare  clinical  entity that  accounts  for less than 1%  of all patients with  Non-
Hodgkin’s lymphoma  and approximately  1.7%  of all  patients with  extralymph 
node  NHL.  Nearly  all patients with  lymphomatous  involvement  of the breast 
had  their   disease   detected  as  palpable   breast   masses   rather  than   by 
mammography.   The tumours   are   comprised  of  large cells   with  round to 
irregular  vesicular  nuclei  variably  prominent  nucleoli  and scant to moderate 
amounts of cytoplasm.  Wiseman  and Liao,  first  defined  clinical  criteria  for the 
classification of primary  breast  lymphoma  including  1) adequate  pathologic 
evaluation  2) mammary tissue in close association  with lymphomatous infiltrate 
3) no evidence of  disseminated  lymphoma other than simultaneous   ipsilateral 
lymph node  involvement and 4) no prior diagnosis of lymphoma55.. 
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In our study,  9 cases  of Phyllodes  tumour  are  observed  in which 6  
cases   are   observed   as   malignant   phyllodes  /  malignant   phyllodes  with 
heterologous  differentiation.
Histological grading is one of the traditional histological prognostic  factors 
in breast  carcinoma.  It is acknowledged  that there are  atleast  three  situations 
in which prognostic  factors are  useful; to  identify  a group of  patients  whose 
prognosis is so  good that adjuvant  therapy would not  be beneficial ; to identify 
patients   whose   outlook   is  so  poor  that   aggressive   adjuvant   therapy   is  
warranted;  to identify  patients who are likely  to  be  responsive or  resistant to a 
particular   type of   therapy.25,26. Omission of Histologic  grading  from clinical 
decision  making may result in overuse  of  adjuvant  therapies in breast  cancer.  
          Pathology has proudly performed the role of “gold standard” in diagnosing 
breast  carcinoma for a long time.  Achieving  high resolution of the details of the  
examined  tissue, histopathology  is still the most sensitive method  in diagnosing 
breast   malignancy   compared  with   the  other   currently    used   imaging 
techniques.   The  so called first   generation  morphologic  prognostic  factors 
(tumour  size, histological  grade, and lymph  node  status)  have  repeatedly  been 
proven  as  reliable  in large,  unselected series of breast  carcinomas as well as in  
series  of  advanced   breast   carcinomas.  These  parameters  as  assessed  by  the 
pathologist represent the basis for staging and are decisive factors in international 
therapy  recommendations.   The   standards   for  interpreting   high  resolution 
histological images  were  already  established  more  than half a century ago  and 
the basic  principles   of   diagnosing,  grading,   typing and  measuring  breast 
lesions have not  substantially changed for decades.42.   
The most  widely accepted system for  grading  invasive breast  carcinoma 
is the Elston-Ellis  system which  represents a  modification of the Scarf-Bloom - 
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Richardson system  established  in the middle  of last century.  Most  practicing 
breast   pathologist   are   trained to   apply  the  Elston  -   Ellis  system and the 
reproducibility of  this grading  system is  well documented.  
Some  tumour  types  have  a  predefined  grade  e.g.   classic  lobular 
carcinomas   are  always   grade   2,  tubular   carcinomas   always  grade  1,  and 
medullary  carcinomas  always grade 3.  The most serious problem in applying 
any  grading  system  is  the  intratumoral  and  intertumoral  heterogeneity 
characterizing   many  breast   carcinomas.   This   means  that  one  cannot  be 
convinced  that  the most aggressive  tumour cell population  within the tumour 
determined  the results of the  grading, although  it may determine the  outcome of 
the   disease.   However  the  advantage   of  giving  a   numerical  parameter  for 
assessing the  biologic   potential of a carcinoma seems to  clearly exceed the 
disadvantages  above,   especially   when   creating    reproducible   treatment 
algorithms.
                Different methods for histological grade  evaluation have been used over  
time.  Although  some authors  have  demonstrated  that  these  approaches have 
almost the  same  potential for  predicting patient survival.  The  basic  problem 
remains that the prognostic value of  histological  grade has been studied in series  
of  patients who are  heterogenous in terms of  stage and treatment and  therefore 
unsuitable for  correctly   determining  the prognostic value.  Moreover,  the  few 
initiatives of interlaboratory quality control   and histological grade evaluations 
have   mainly highlighted unsatisfactory  concordance results with correlation  co-
efficients  more  frequently around 0.55 and  never higher  than 0.75.
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A comparative  analysis  of  proportion of  grade I,  grade II  and grade III 
breast cancers by various studies are given in the following Table 20.
TABLE . 20
COMPARISON OF RELATIVE PERCENTAGE OF CASES IN EACH 
GRADE
S.No. Study & Year GradeI II III
1. Bloom and Richardson 1957 26 45 29
2. Tough et al., 1957 11 51 38
3. Champion, Wallace & Prescott 1972 23 52 25
4. Fisher et al., 1984 17 37 46
5. Elston 1984 17 37 46
6. Doris et al., 1986 22 49 22
7. Contesso et al., 1987 21 30 29
8. Hopton et al., 1989 29 45 26
9. Le Donssal et al., 1989 11 55 46
1
0.
Study – Thanjavur Medical College 2002-
2003 38.8 50 11.2
1
1.
Present Study
9.2 66.42 24.28 
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In our  study, most of the breast  cancers are  in the grade II in contrast with the 
western  literature  where more cases are  picked up  in the early stages. In our 
study 24% of cases are seen in well advanced stage,  grade III.
Two difficult cases are also  subjected  for  immunohistochemical  markers 
studies as in the following  table: 21
Table . 21
S.NO. HISTOPATHOLOGICAL  DIAGNOSIS MARKER RESULT IMPRESSION
1. Malignant Phyllodes with 
heterologous 
rhabdomyosarcomatous 
differentiation (Fig 48 a,b)
Actin 
Desmin
POSITIV
E
POSITIV
E
Malignant   Phyllodes 
with  heterologous 
rhabdomyosarcomatous 
differentiation
2. Adenomyoepithelioma 
with ? malignancy 
(Fig 49)
Smooth 
muscle 
actin
Positive Adenomyoepithelioma
Relative incidence of breast  malignancies are given in the following table : 22.
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TABLE -22
RELATIVE INCIDENCES OF MALIGNANT TUMOURS
S.No. Type of Malignancy Anderson et al., Rosen
Fisher 
et al.,
Ellis 
et al.,
Tata 
Memorial, 
Mumbai
Study at Thanjavur 
Medical College 
2002-2003
Present 
Study
I
a) 
NON INVASIVE
Ductal 8% 6.45%
b) Lobular 2%
II
a)
INVASIVE
Ductal carcinoma-NOS 60% 75% 53% 49% 88% 86.91% 78.23%
b) Special Types 30% 5.35% 15.44%
Lobular 15% 10% 5% 16% 4% 0.64% 1.36%
Medullary 7% 9% 6% 3% 2% 0.64% 0.68%
Tubular 5% 2% 1% 2%
Mucinous 5% 2% 2% 1% 1.94% 2.72%
Papillary 0.64% 3.4%
Metaplastic carcinoma 2.72%
Other Rare Types
Infiltrating cribriform Ca 0.68%
Infiltrating micropapillary  
Ca
0.68%
Adenoid cystic carcinoma 0.68%
Adenomyoepithelioma with  
malignancy 
0.68%
Neuroendocrine tumour 0.68%
III Malignant Phyllodes 1.29% 4.08%
IV Mesenchymal tumours 2.04%
V Lymphoma 0.68%
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CONCLUSION
In the present prospective study of 267 cases of breast neoplasms, evaluated 
with clinical, light microscopy, histochemical and immunohistochemical markers, 
following  conclusions are made and presented.
1. The  average  incidence  of breast  neoplasms is 24.30%.
2. The average incidence of  breast malignancies in relation to total number of 
cancers in females is 17.50%.
3. The incidence  of breast   neoplasm is  steady  and slowly  progressive 
without any abrupt increase.
4. Early  menarche and early age of first  child birth are the only two clinical 
parameters  found in  association with  breast  cancer.
5. Mammography  and  fine  needle  aspiration  remains  as  gold  standard  in 
initial evaluation of breast lump. 
6. Upper and outer  quadrant is the  preferable site for all breast  lumps
7. Conventional fibroadenoma is the  commonest  benign breast  neoplasm.
8. In conventional  fibroadenoma, pericanalicular  fashion is common.
9. Benign neoplasms  commonly occur  between 15-30 years.
10. Infiltrating  Ductal  Carcinoma  (NOS)  is  the  commonest  malignant 
neoplasm  with  trabecular pattern.
11. Malignant  neoplasms  commonly occur between 30-60 years.
12. No age is exempt for breast cancer since one case is also observed  at  the  
age of five.
13. Non epithelial malignant tumours  commonly occur in the post menopausal 
age group.
14. Fibro epithelial phyllodes tumour  commonly  present in an advanced stage.
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15. Grading is a very useful protocol in evaluation, management and further 
prognosis.
16. Most of the epithelial malignancies are seen as grade II.
17. Modified Bloom Richardson method - Elston & Ellis grading with tubular 
and glandular formations, nuclear pleomorphism and mitotic count stands 
as the best method for grading epithelial tumours. 
18. Grading of fibroepithelial phyllodes tumour is done separately by taking 
morphological factors such as stromal cellularity, cellular  pleomorphism , 
mitosis , margins, stromal pattern and heterologous stromal differentiation 
for scoring
19. In case of doubtful  diagnosis,  immunohistochemistry is  very  useful  for 
further confirmation 
The majority of breast carcinomas in young women are invasive, with T2 
disease at presentation and of poor histological grade.  The recent rise in numbers 
suggests increased detection, possibly due to improved awareness of breast disease 
among the younger  female population.
The urgent need for  improved screening techniques  for early  detection 
and for an aggressive health  education compaign to increase the  awareness  of 
women about the potential risk of  breast cancer  and early detection by regular 
testing  like  mammography   and  fine  needle   aspiration   studies   improves 
survival. 
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APPENDIX – I
HAEMATOXYLIN AND EOSIN
Preparation of the solution : 
Distilled water - 1000ml
Ammonium alum - 100g
Haematoxylin - 5g
Absolute ethylalcohol - 50ml
Mercuric Oxide - 2.5g
100g of ammonium alum dissolved in 1000ml of distilled water by heating 
nad shaking at 60°C. Add solution of 50g of haematoxylin in 50ml of ethyl alcohol 
and bring rapidly to boil. When it begins to boil, remove from flame and add 2.5g 
of Mercuric oxide. Mix by swirling gently. 
EOSIN STAIN 
    Eosin Y - 1g
Distilled water - 20ml
95% ethanol - 80ml
Glacial acetic acid - 0.2ml
Dissolve 1g eosin Y in 20ml of water add 06% ethanol and glacial acetic acid. 
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PROCEDURE 
 Sections to water. 
 Harris’s hematoxylin for 15 minutes. 
 Rinse in tap water. 
 Differentiate in acid alcohol – 3 to 10 quick dips. 
 Wash in tap water very briefly. 
 Dip in ammonia water (for 10-20 seconds) saturated lithium carbonate until 
sections are bright blue. 
 Wash in running tap water for 10-20 minutes. 
 Stain with eosin for 15 seconds to 2 minutes depending in the age of the 
eosin and the depth of counter stain required. 
 95% alcohol. 
 Absolute alcohol – at least 2 changes. 
 Xylene – 2 changes. 
 Mount in DPX mountant.
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APPENDIX – II
MAY GRUNWALD GIEMSA
1. Air dry the smear
2. Fix by immersing in a jar  of methanol           - 5 to10 minutes
3. Transfer to a staining jar containing 
MAY GRUNWALD stain freshly diluted with an -15 minutes
 equal volume of buffered water
4. Transfer the slide without washing to a jar 
containing giemsa stain freshly diluted with 9 - 10 to15 minutes
volume of buffered water 
5. Wash with buffered water
6. Dry and mount. 
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APPENDIX-III
PERIODIC ACID SCHIFF TECHNIQUE
Solution required
a) 1.5% periodic acid.
b) Mayer’s haemalum
c) Sulphurous acid
Sodium metabisulphite 10% 6 ml
N/I hydrochloric acid 10% 5 ml
Distilled water 100 ml
(d). Schiffs reagent
Basic fuchsin 1 gm
Sodium metabisulphite, anhydrous 1 gm
Distilled water 200 ml
 N/I hydrochloric acid 20 ml
Boil the distilled water; add basic fuchsin and Stir, Cool to 50° C.
Then  filter  and  add  hydrochloric  acid,  Cool  to  25°C  and  add  the  sodium 
metabisulphite.
This solution is ready for use when it becomes nearly colourless, which may take 
up to two days in the dark.
(Alternatively  activated  charcoal  may  be  added  to  the  solution,  shaken  and 
filtered). The  solution becomes recoloured it should be discarded.
73
Technique 
1) Section to water
2) Periodic acid 0.5% 5 minutes
3) Rinse in distilled water
4) Schiff’s reagent 15 minutes
5) Rinse in the three fresh changes of sulphurous acid
2 minutes in each change 6 minutes
6) Wash in running tap each changes 5 minutes
7) Counterstain in Mayer’s haemalum 30 seconds
8) Wash in running tap water 5 minutes
9) Dehydrate, clear and mount
Results
Positive material: reddish – purple
Nucleus: faint grey 
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APPENDIX – IV
IMMUNO-HISTOCHEMISTRY
Method Used : 
1. 5u  thick  sections  were  cut  from  the  blocks  received  (diagnosed  a 
lymphomas) on slides coated with Chrome alum gelatin. 
2. Slides were dewaxed and dehydrated in graded alcohol. 
3. Slides were immersed in 0.3% H2O2 for 20 minutes to block endogenous 
peroxidase activity. 
4. Washed in phosphate buffered saline (PBS). 
5. Incubated in Primary Antibody & Pan G (CD20, clove L26 DAKO) and 
PAN T (CD3, Polyclonal, DAKO) for 20 minutes. 
6. Washed in PBS. 
7. Biotinylated link was applied for 20 minutes. 
8. Washed in PBS. 
9. Incubated in streptavin-biotin complex. 
10. Washed in PBS. 
11. DAB was used as chromogen
12. Washed and can be stained with haematoxylin. 
13. Mounted with coverslip. 
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